Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88(WT)) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2 pivotal study. Zanubrutinib is a novel, selective Bruton tyrosine kinase (BTK...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Dimopoulos, Meletios, Sanz, Ramon Garcia, Lee, Hui-Peng, Trneny, Marek, Varettoni, Marzia, Opat, Stephen, D'Sa, Shirley, Owen, Roger G., Cull, Gavin, Mulligan, Stephen, Czyz, Jaroslaw, Castillo, Jorge J., Motta, Marina, Siddiqi, Tanya, Gironella Mesa, Mercedes, Granell Gorrochategui, Miquel, Talaulikar, Dipti, Zinzani, Pier Luigi, Askari, Elham, Grosicki, Sebastian, Oriol, Albert, Rule, Simon, Kloczko, Janusz, Tedeschi, Alessandra, Buske, Christian, Leblond, Veronique, Trotman, Judith, Chan, Wai Y., Michel, Jan, Schneider, Jingjing, Tan, Ziwen, Cohen, Aileen, Huang, Jane, Tam, Constantine S.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724905/
https://ncbi.nlm.nih.gov/pubmed/33284944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars